Mark Montgomery, MD
University of Calgary
3
3
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Grace E Parraga, PhD
Robarts Research Institute, The University of Western Ontario
Shared therapeutic areas:
Melda Saglam, PhD
Hacettepe University
Shared therapeutic areas:
Avindra Nath, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Shared therapeutic areas:
Mehwish Waseem, MSPT(CPPT)
Riphah International University
Shared therapeutic areas:
Naciye Vardar-Yagli, PhD
Hacettepe University
Shared therapeutic areas:
Rémi Rabasa-Lhoret
Institut de Recherches Cliniques de Montreal
Shared therapeutic areas:
Xiaolong Qi, MD
LanZhou University
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Averell Sherker, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
All 3 trials loaded